On Thursday, Shares of Halliburton Company (NYSE:HAL), lost -0.21% to $38.09.
Two of Halliburton’s Brazilian facilities – Macaé and Rio de Janeiro – and nine of the company’s business lines located there have received the American Petroleum Institute (API) Specification Q2 Certification, an advanced industry certification standard for oil and natural gas service companies. They are the first in Latin America to receive the certification.
The business lines that achieved the certification are Baroid, Cementing, Completion Tools, Drill Bits and Services, Production Enhancement, Production Solutions, Sperry Drilling, Testing and Subsea, and Wireline and Perforating.
API Q2 is a risk-based quality administration system approach that focuses on competency, service design, contingency planning, supply chain controls, preventive maintenance, inspection, service quality plans and administration of change. It is the first international standard that outlines fundamental, risk-based quality administration systems for oil and natural gas services companies. The certification demonstrates an organization’s commitment to exceed current generic quality administration system standards.
“The API Spec Q2 Certification is a step change in the industry and a recognition to Halliburton’s commitment to improve operational efficiency with a flawless execution of our services,” said Daniel Casale, country manager, Brazil for Halliburton.
“API Spec Q2 Certification has set the standard for the oil and natural gas service providers around the globe,” said Gerardo Uría, API’s acting Vice President for Global Industry Services. “API Spec Q2 Certified Facilities operate under a stringent quality-administration system that assists minimize risks and contributes to a safer operating environment for the industry. With the recent certification of the Macaé and Rio de Janeiro facilities, Halliburton continues to be a leader in the implementation of API Spec Q2 and demonstrates its commitment to operational integrity.”
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
Shares of Merck & Co., Inc (NYSE:MRK), declined -0.62% to $52.65, during its last trading session.
Merck (MRK), known as MSD outside the United States and Canada, recently declared that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND® (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. With this expanded indication, EMEND capsules are now approved for use in combination with other antiemetic agents in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg (about 66 pounds) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) counting high-dose cisplatin, in addition to for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND has not been studied for treatment of established nausea and vomiting. Chronic continuous administration of EMEND is not recommended because it has not been studied, and because the drug interaction profile may change during chronic continuous use.
With this approval, EMEND is the first and only NK1 receptor antagonist to be approved for the prevention of acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV) in patients 12 to 17 years of age and patients less than 12 years who weigh at least 30 kg receiving HEC or MEC. The approval was supported by data from a pivotal Phase 3 study that showed adding EMEND to a standard regimen for prevention of CINV in HEC or MEC regimens resulted in a reduction of emetic events.
EMEND is contraindicated in patients with any known sensitivity to any component of this drug. EMEND is also contraindicated for patients taking pimozide.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, McCormick & Company, Incorporated (NYSE:MKC), ended its last trade with 1.14% gain, and closed at $80.08.
McCormick & Company, a global leader in flavor, will be presenting at the Barclays Global Consumer Staples Conference at 11:15 a.m. EDT, on September 10, 2015 in Boston, MA. Representing McCormick will be Lawrence Kurzius, President & Chief Operating Officer and Gordon Stetz, Executive Vice President & Chief Financial Officer. The presentation will be web cast live via the McCormick web site ir.mccormick.com.
What: McCormick & Co. presentation at Barclays Global Consumer Staples Conference
When: September 10, 2015, at 11:15 a.m. ET
McCormick & Company, Incorporated manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavorful products to the food industry worldwide. It operates through two segments, Consumer and Industrial. The Consumer segment offers spices, herbs, seasonings, and dessert items under the McCormick, Lawrys, Club House, Zatarains, Thai Kitchen, Simply Asia, Ducros, Schwartz, Kamis, Vahiné, DaQiao, Aeroplane, and Kohinoor brand names, in addition to supplies private label items.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
